- Case report
- Open Access
- Open Peer Review
Percutaneous septal ablation for left mid-ventricular obstructive hypertrophic cardiomyopathy: a case report
© Tengiz et al; licensee BioMed Central Ltd. 2006
- Received: 03 March 2005
- Accepted: 10 April 2006
- Published: 10 April 2006
Mid-ventricular obstructive hypertrophic cardiomyopathy (MVOHC) is a rare type of cardiomyopathy. The diagnosis is based on the hourglass appearance on the left ventriculogram and the presence of pressure gradient between apical and basal chamber of the ventriculum on the hemodynamic assessment.
The present case represents successful percutaneous treatment with septal ablation to patient with MVOHC associated with systolic anterior motion of the mitral valve and obstruction at both the mid-ventricular and outflow levels.
Alcohol septal ablation has been proposed as less invasive alternatives to surgery in patients with MVOHC.
- Mitral Valve
- Left Ventricular Outflow Tract
- Myocardial Contrast Echocardiography
- Systolic Anterior Motion
- Septal Branch
Hypertrophic cardiomyopathy (HC) is a hereditary myocardial disorder, caused by mutations of sarcomeric proteins . In roughly 25% of cases of HC there is associated obstruction to left ventricular (LV) outflow . Obstruction can occur at several locations within the ventricle, depending on the distribution of hypertrophy, including a) the mitral valve level in association with systolic anterior motion (SAM) of the mitral valve; b) the mid-ventricle; or c) within the cardiac apex .
In about 5% of patients a mid-ventricular obstruction (MVO) can be observed . These patients are often symptomatic from hemodynamic causes and are also prone to symptomatic and even lethal ventricular arrhythmias. MVO may be associated with hypertrophy of the papillary muscle(s) and apical LV aneurysm. MVO usually presents as local obstruction but can be associated with SAM and obstruction at both the mid-cavitary and outflow levels .
During the past 10 years, atrio-ventricular sequential pacing and alcohol septal ablation have been proposed as less invasive alternatives to surgery for patients who fail to respond to pharmacologic therapy [3, 4]. However, atrio-ventricular sequential pacing is not currently thought to be dramatically beneficial [5, 6]. We report on percutaneous septal ablation in a patient with left mid-ventricular obstructive hypertrophic cardiomyopathy (MVOHC) associated with SAM of the mitral valve and obstruction at both the mid-ventricular and outflow levels, which seems to be an alternative therapy in these patients.
The post-procedural echocardiographic examination was done before the discharge and showed reductions of left atrial dimension to 46 mm and interventricular septum thickness to 20 mm with septal hypokinesia and mild mitral regurgitation without SAM of the mitral valve. LV end-diastolic and end-systolic diameters were 49 mm, 32 mm respectively. Continuous-wave Doppler measurements showed 21 mmHg a peak systolic resting gradient, with an increase to 36 mmHg at Valsalva's maneouvre (Figure 3C). The patient was discharged after an uneventful hospital stay of 5 days. Medication with 100 mg metoprolol was continued at discharge.
Obstruction at lower levels of the ventricle simply reflects partial obliteration of the ventricular cavity by the contracting hypertrophied muscle in the face of continued ejection of blood. An asynergic or aneurismal apical chamber in the absence of fixed coronary artery disease has been previously described in patients with MVO . It has been suggested that the development of apical aneurysm may be secondary to increased afterload and high apical pressure resulting from a systolic MVO . Therefore, relief of the high apical pressure may be necessary preventing further asynergy.
Myectomy has been employed primarily in patients with obstruction at the mitral valve level. Because obstruction primarily relates to SAM of the mitral valve, some have recommended mitral valve replacement as the most direct method for relieving obstruction . Mitral valve replacement has also been recommended for patients with direct insertion of the papillary muscle into the anterior mitral leaflet and associated MVO, although this strategy is undesirable for young patients. In these cases, extending and broadening the myectomy in the mid-ventricle and mobilizing the papillary muscle with valve preservation has been reported with good success .
Non-surgical treatment options for the obstructive cardiomyopathies are performed to increasing number of patients to reduce hospitalization duration and cost. With DDD pacing the outflow gradient can be reduced more than 30%. Randomized trials have shown a limited hemodynamic and clinical improvement in severely symptomatic patients with hypertrophic obstructive cardiomyopathy . Although there are a few report of a therapeutic effect of DDD pacing in MVO [11, 12], it can not be recommended for routine application due to failure of reliable predictability of individual therapeutic success .
Nonrandomized reports comparing septal ablation with myectomy describe similar degrees of LV outflow tract gradient reduction with follow-up between 3 months and 1 year . Additionally, improvements in clinical endpoints, such as quality of life and functional status, have been comparable, suggesting that septal ablation is a safe and effective alternative to myectomy in select patients. However, occlusion of the septal branches is generally ineffective for reducing the intra-ventricular pressure gradient if they do not supply the obstructive muscle mass. The most important problem is the identification of the target vessel. Variability in the size and distribution of the first septal branch in patients with HC is substantial. Areas of the heart other than the basal septum are supplied in some patients by the first septal branch. In other patients the first septal branch is not supply the entire basal septum. A detailed evaluation of the distribution of the first septal branch may be necessary in all patients with HC who are undergoing alcohol septal ablation . Echocardiographic monitoring is indispensable in order to identify the target vessel and to exclude alcohol misplacements.
The fourth septal branch ablation for pressure gradient reduction in patients with MVOHC has been reported by Seggewiss et al . The present case had MVOHC associated with SAM of the mitral valve and obstruction at both the mid-ventricular and outflow levels. In addition, the first septal branch was pretty dominant and considered that alcohol ablation can be effective in decreasing the intra-ventricular pressure gradient. Likewise, the echocontrast injection in the first septal branch resulted with the largest echocontrast view in hypertrophic muscle segment. Furthermore, transient occlusion of the vessel by balloon inflation resulted in significant decrease in intra-ventricular pressure gradient. Therefore, the first septal branch was assumed as a target vessel and occlusion of the vessel resulted with a significant and sustained reduction of symptoms.
There are multiple factors cause severe arrhythmias during the procedure, including ischemia, infarction, and the presence of an arrhythmogenic myofibrillar substrate, local-tissue toxicity from the alcohol and echocontrast agent. Although were not seen in our case, total AV block and ventricular fibrillation may occur with application of echovist in the systemic arterial circulation. Therefore, levovist is appropriate echo contrast agent for septal ablation . Development of LV myocardial damage, heart failure, ventricular septal defect, dysfunction of papillary muscles and severe rhythm disturbances such as permanent or transient atrioventricular block required pacemaker implantation are important limitations of this procedure .
In summary, percutaneous septal ablation may be useful in patients with MVOHC accompanying with LV outflow tract obstruction. Echocardiographic monitoring in alcohol induced percutaneous myocardial ablation enables the widening of morphological indication to patients with MVOHC. Septal ablation in MVOHC is not classical and wide accepted treatment in contrast to the subaortic type LV obstruction. Possible complications and unknown long-term effects require careful patient selection as well as experience in interventional cardiology and hypertrophic cardiomyopathy.
- Yoerger DM, Weyman AE: Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. Rev Cardiovasc Med. 2003, 4: 199-215.PubMedGoogle Scholar
- Wigle ED, Rakowski H: Hypertrophic cardiomyopathy: when do you diagnose midventricular obstruction versus apical cavity obliteration with a small nonobliterated area at the apex of the left ventricle?. J Am Coll Cardiol. 1992, 19: 525-526.View ArticlePubMedGoogle Scholar
- Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH: A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy – the Baylor experience (1996–2002). Clin Cardiol. 2005, 28: 124-130.View ArticlePubMedGoogle Scholar
- Kappenberger LJ, Linde C, Jeanrenaud X, Daubert C, McKenna W, Meisel E, Sadoul N, Chojnowska L, Guize L, Gras D, Aebischer N, Gadler F, Ryden L: Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group. Europace. 1999, 2: 77-84. 10.1053/eupc.1998.0024.View ArticleGoogle Scholar
- Dimitrow PP, Podolec P, Grodecki J, Plazak W, Dudek D, Pieniazek P, Bacior B, Legutko J, Olszowska M, Kostkiewicz M, Kawecka-Jaszcz K, Tracz W, Dubiel JS: Comparison of dual-chamber pacing with nonsurgical septal reduction effect in patients with hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2004, 94: 31-34. 10.1016/j.ijcard.2003.03.010.View ArticlePubMedGoogle Scholar
- Gietzen FH, Schummelfeder J, Neuser H, Brunn J, Schumacher B, Kerber S: Interventional Treatment in Hypertrophic Cardiomyopathy. Herz. 2005, 30: 102-110. 10.1007/s00059-005-2675-8.View ArticlePubMedGoogle Scholar
- Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S: Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998, 31: 252-258. 10.1016/S0735-1097(97)00508-1.View ArticlePubMedGoogle Scholar
- Nakamura T, Matsubara K, Furukawa K, Azuma A, Sugihara H, Katsume H, Nakagawa M: Diastolic paradoxic jet flow in patients with hypertrophic cardiomyopathy: Evidence of concealed apical asynergy with cavity obliteration. J Am Coll Cardiol. 1992, 19: 516-524.View ArticlePubMedGoogle Scholar
- Fighali S, Krajcer Z, Edelman S, Leachman RD: Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: High incidence in patients with midventricular obstruction. J Am Coll Cardiol. 1987, 9: 288-294.View ArticlePubMedGoogle Scholar
- Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, Allison TG, Tajik AJ: Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double blind, crossover trial. J Am Coll Cardiol. 1997, 29: 435-441. 10.1016/S0735-1097(96)00473-1.View ArticlePubMedGoogle Scholar
- Watanabe H, Kibira S, Saito T, Shimizu H, Abe T, Nakajima I, Iino K, Miura M: Beneficial effect of dual-chamber pacing for a left mid-ventricular obstruction with apical aneurysm. Circ J. 2002, 66: 981-984. 10.1253/circj.66.981.View ArticlePubMedGoogle Scholar
- Begley D, Mohiddin S, Fananapazir L: Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2001, 24: 1639-1644. 10.1046/j.1460-9592.2001.01639.x.View ArticlePubMedGoogle Scholar
- Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH: Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001, 38: 1701-1706. 10.1016/S0735-1097(01)01614-X.View ArticlePubMedGoogle Scholar
- Singh M, Edwards WD, Holmes DR, Tajil AJ, Nishimura RA: Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc. 2001, 76: 799-802.View ArticlePubMedGoogle Scholar
- Seggewiss H, Faber L: Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiogr. 2000, 1: 277-280. 10.1053/euje.2000.0032.View ArticlePubMedGoogle Scholar
- Becher H: Contrast echocardiography: clinical applications and future prospects. Herz. 2001, 27: 201-216. 10.1007/s00059-002-2371-x.View ArticleGoogle Scholar
- Zhang W, Li Z, Zhang M, Yuan L, Guan R, Hou A, Jin Y, Deng Z: Complications of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Chin Med J (Engl). 2002, 115: 1283-1286.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/6/15/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.